PURPOSE: Whole-brain irradiation (WBI) leads to cognitive impairment months to years after radiation. Numerous studies suggest that decreased hippocampal neurogenesis and microglial activation are involved in the pathogenesis of WBI-induced brain injury. The goal of this study was to investigate whether administration of the peroxisomal proliferator-activated receptor (PPAR) alpha agonist fenofibrate would prevent the detrimental effect of WBI on hippocampal neurogenesis. METHODS AND MATERIALS: For this study, 129S1/SvImJ wild-type and PPARalpha knockout mice that were fed either regular or 0.2% wt/wt fenofibrate-containing chow received either sham irradiation or WBI (10-Gy single dose of (137)Cs gamma-rays). Mice were injected intraperitoneally with bromodeoxyuridine to label the surviving cells at 1 month after WBI, and the newborn neurons were counted at 2 months after WBI by use of bromodeoxyuridine/neuronal nuclei double immunofluorescence. Proliferation in the subgranular zone and microglial activation were measured at 1 week and 2 months after WBI by use of Ki-67 and CD68 immunohistochemistry, respectively. RESULTS: Whole-brain irradiation led to a significant decrease in the number of newborn hippocampal neurons 2 months after it was performed. Fenofibrate prevented this decrease by promoting the survival of newborn cells in the dentate gyrus. In addition, fenofibrate treatment was associated with decreased microglial activation in the dentate gyrus after WBI. The neuroprotective effects of fenofibrate were abolished in the knockout mice, indicating a PPARalpha-dependent mechanism or mechanisms. CONCLUSIONS: These data highlight a novel role for PPARalpha ligands in improving neurogenesis after WBI and offer the promise of improving the quality of life for brain cancer patients receiving radiotherapy.
PURPOSE: Whole-brain irradiation (WBI) leads to cognitive impairment months to years after radiation. Numerous studies suggest that decreased hippocampal neurogenesis and microglial activation are involved in the pathogenesis of WBI-induced brain injury. The goal of this study was to investigate whether administration of the peroxisomal proliferator-activated receptor (PPAR) alpha agonist fenofibrate would prevent the detrimental effect of WBI on hippocampal neurogenesis. METHODS AND MATERIALS: For this study, 129S1/SvImJ wild-type and PPARalpha knockout mice that were fed either regular or 0.2% wt/wt fenofibrate-containing chow received either sham irradiation or WBI (10-Gy single dose of (137)Cs gamma-rays). Mice were injected intraperitoneally with bromodeoxyuridine to label the surviving cells at 1 month after WBI, and the newborn neurons were counted at 2 months after WBI by use of bromodeoxyuridine/neuronal nuclei double immunofluorescence. Proliferation in the subgranular zone and microglial activation were measured at 1 week and 2 months after WBI by use of Ki-67 and CD68 immunohistochemistry, respectively. RESULTS: Whole-brain irradiation led to a significant decrease in the number of newborn hippocampal neurons 2 months after it was performed. Fenofibrate prevented this decrease by promoting the survival of newborn cells in the dentate gyrus. In addition, fenofibrate treatment was associated with decreased microglial activation in the dentate gyrus after WBI. The neuroprotective effects of fenofibrate were abolished in the knockout mice, indicating a PPARalpha-dependent mechanism or mechanisms. CONCLUSIONS: These data highlight a novel role for PPARalpha ligands in improving neurogenesis after WBI and offer the promise of improving the quality of life for brain cancerpatients receiving radiotherapy.
Authors: Radoslaw Rola; Jacob Raber; Angela Rizk; Shinji Otsuka; Scott R VandenBerg; Duncan R Morhardt; John R Fike Journal: Exp Neurol Date: 2004-08 Impact factor: 5.330
Authors: Shinichiro Mizumatsu; Michelle L Monje; Duncan R Morhardt; Radoslaw Rola; Theo D Palmer; John R Fike Journal: Cancer Res Date: 2003-07-15 Impact factor: 12.701
Authors: Jacob Raber; Radoslaw Rola; Anthony LeFevour; Duncan Morhardt; Justine Curley; Shinichiro Mizumatsu; Scott R VandenBerg; John R Fike Journal: Radiat Res Date: 2004-07 Impact factor: 2.841
Authors: Christine T Ekdahl; Jan-Hendrik Claasen; Sara Bonde; Zaal Kokaia; Olle Lindvall Journal: Proc Natl Acad Sci U S A Date: 2003-10-27 Impact factor: 11.205
Authors: Tammy C Lee; Dana Greene-Schloesser; Valerie Payne; Debra I Diz; Fang-Chi Hsu; Mitra Kooshki; Rashida Mustafa; David R Riddle; Weiling Zhao; Michael D Chan; Mike E Robbins Journal: Radiat Res Date: 2012-06-12 Impact factor: 2.841
Authors: Christina K Cramer; Tiffany L Cummings; Rachel N Andrews; Roy Strowd; Stephen R Rapp; Edward G Shaw; Michael D Chan; Glenn J Lesser Journal: Curr Treat Options Oncol Date: 2019-04-08
Authors: Munjal M Acharya; Lori-Ann Christie; Mary L Lan; Erich Giedzinski; John R Fike; Susanna Rosi; Charles L Limoli Journal: Cancer Res Date: 2011-07-14 Impact factor: 12.701
Authors: Dana Greene-Schloesser; Valerie Payne; Ann M Peiffer; Fang-Chi Hsu; David R Riddle; Weiling Zhao; Michael D Chan; Linda Metheny-Barlow; Mike E Robbins Journal: Radiat Res Date: 2014-01-07 Impact factor: 2.841
Authors: A A Martinez; M G Morgese; A Pisanu; T Macheda; M A Paquette; A Seillier; T Cassano; A R Carta; A Giuffrida Journal: Neurobiol Dis Date: 2014-12-05 Impact factor: 5.996
Authors: Dana M Greene-Schloesser; Mitra Kooshki; Valerie Payne; Ralph B D'Agostino; Kenneth T Wheeler; Linda J Metheny-Barlow; Mike E Robbins Journal: Int J Radiat Biol Date: 2014-09 Impact factor: 2.694